We examined the clinical features and therapeutic response of a group of patients with acute leukemia and hypocellular bone marrow. Therapists have generally avoided, delayed or modified therapy because of hypocellularity. We demonstrated not only that aggressive therapy is possible, but also that the remission rate is high (complete remission = 73 percent) and survival prolonged (x̄ > 40 months).
Bibliographical noteFunding Information:
From the Sections of Hematology and Medical Oncology, Department of Medicine and the Department of Laboratory Medicine and Pathology, University of Minnesota Medical School, Minneapolis, Minnesota. This work was supported in part by the Ernest Johnson Memorial Leukemia Research Fund, NHLB Training Grant #5T32 HL07062, the Masonic Hospital Foundation and the Minnesota Medical Foundation. Reprint requests should be addressed to Dr. Robert Howe, University of Minnesota Hospitals, Box 480 Mayo Memo&l Building, Minneapolis, Minnesota 55455. Manuscript accepted October 6, 196 1.